🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms,

#ACC25 Day 2, here is the summary of today’s trials (I haven’t included the follow-up extensions of Evolut Low Risk, Triluminate, and FAME 3). Today, I counted at least 2 NEJM, 4 Lancet, 1 Nature, 1 JAMA, 1 Circulation, and 1 JACC. 1. MIGHTy-Heart = In-home paramedic visits for

Proud of our fellows @ufjaxcatds presenting at #ACC25 Special shout out to khalid featured #ACC25 interview of our terrific case - now in print as well. American College of Cardiology Cristina Font, MD César Joel Benites Moya @maelynntravels jacc.org/digital-conten…

Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study European Society of Cardiology Journals academic.oup.com/eurheartj/arti…

🧠 Just Published: State-of-the-Art Review Rethinking Cardiovascular Risk: The emerging role of lipoprotein(a) screening in prevention and early detection. 📝 A must-read for anyone involved in cardiovascular care. 🔗 Check it out: ow.ly/hmI350VvUzH

📢NEW NLA & American Geriatrics Society expert clinical consensus on managing #hypercholesterolemia in adults older than 75 years without a history of #ASCVD. Read the article now: sciencedirect.com/science/articl…

Gut microbiota pattern is associated with occurrence of cardiovascular events in patients with established ischemic heart disease. Read the results of the CORDIOPREV study in #EHJ 👉 ow.ly/PG0Z50VyHXe Rocco Montone EHJ Editor-in-Chief #gutmicrobiota

A significant burden of elevated Lp(a) was observed in a large health check-up population in China & elevated Lp(a) was associated w/ site-specific subclinical atherosclerosis & a stronger association w/ severe extent & multisite involvement. More: bit.ly/4jR5sBL #JACC

🛌💔 New research: Sleep disorders may increase risk for calcific aortic stenosis. Explore this emerging connection in the latest study 👇 🔗 ow.ly/cTzR50VJZr5 #Cardiology #SleepHealth #AorticStenosis #HeartValveDisease #MedTwitter

"The human heart is a miraculous organ. It supplies itself before it serves others, a lesson we all could live by.” Dr. Helen Taussig

It’s not just the heartbeat that keeps us alive, it’s the intricate web of microvessels, each one silently fueling life. The heart isn’t a pump. It’s an orchestra.

Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database academic.oup.com/eurheartj/arti…

The BROADWAY trial assesses the safety and efficacy of obicetrapib among patients at high risk for cardiovascular events. Get more details ➡️ bit.ly/4mmYQx6 #CardioX

Target Populations for Novel Triglyceride-Lowering Therapies | JACC jacc.org/doi/epdf/10.10…

Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques: A PROSPECT II Substudy | JACC jacc.org/doi/10.1016/j.…

With almost 12,000 patients undergoing Light Trasmission Aggregometry over 20 years, this study is among the largest exploring sex-related variability in platelet reactivity, highlighting potential implications for personalized antiplatelet therapy. bit.ly/4kGEdu4

The intersectionality of cardiac amyloidosis, aging and frailty is the focus of a State-of-the-Art Review published in #JACCAdvances. Read the journal scan to learn more: bit.ly/4dzdOvG #cvGeri

📉Lower LDL-C for longer is better. The NLA’s new guidance simplifies LDL-C management for adults — helping clinicians & patients improve evidence-based measurement and treatment of LDL-C. Read the guidelines & recommendations: lipidjournal.com/article/S1933-…. Beth Jackson Christie Ballantyne

In the BROADWAY trial involving patients at high cardiovascular risk, the cholesteryl ester transfer protein inhibitor obicetrapib reduced low-density lipoprotein cholesterol levels by 29.9% at 84 days. Full trial results and Research Summary: nej.md/4lKsmMK

ApoB and Lp(a): core measures to assess cardiovascular risk academic.oup.com/eurheartj/arti…